1. PNPLA3 gene predicts clinical recovery after sustained virological response in decompensated hepatitis C cirrhosis
- Author
-
Winston Dunn, Anusha Vittal, Jianghua He, Shweta Chakraborty, Melissa Whitener, Sara Fohn, Ryan Ash, Ryan M Taylor, Mojtaba Olyaee, Jody C Olson, Nancy Todd, Beth N Floyd, Prashant Pandya, Melissa Laycock, Timothy Schmitt, and Steven A Weinman
- Subjects
Diseases of the digestive system. Gastroenterology ,RC799-869 - Abstract
BackgroundPatients with decompensated hepatitis C virus (HCV) cirrhosis experience various outcomes after sustained virological response (SVR), ranging from clinical recovery to further deterioration. We hypothesised that the genetic risk for steatosis, namely the polymorphisms rs738409 of Patatin-like Phospholipase Domain-Containing 3 (PNPLA3), rs58542926 of Transmembrane-6-Superfamily-2 (TM6SF2), and rs641738 of Membrane-bound O-acyltransferase Domain-Containing 7 (MBOAT7), is predictive of recovery.MethodsWe prospectively enrolled 56 patients with Child-Pugh (CPT) B/C cirrhosis who underwent antiviral therapy. The primary outcome was change in CPT score at 12, 24, and 48 weeks after SVR. We used a linear mixed-effects model for analysis.ResultsForty-five patients (PNPLA3: 21 CC, 19 CG, 5 GG) survived to the first endpoint without liver transplantation. The mean change in CPT score at 12, 24, and 48 weeks was −1.57 (SE=0.30), –1.76 (SE=0.32), and −2.0 (SE=0.36), respectively, among the patients with the PNPLA3 CC genotype and −0.50 (SE=0.20), –0.41 (SE=0.25), and −0.24 (SE=0.27), respectively, among the other 24 patients. After adjustment for baseline characteristics, the PNPLA3 CG/GG genotypes were associated with a 1.29 (SE=0.30, p
- Published
- 2019
- Full Text
- View/download PDF